Cannabis Bioscience International Holdings, Inc.
Raising nowPublicBiotech · Houston, TX
Cannabis Bioscience International Holdings runs clinical trials, some involving cannabis and CBD products, as a sponsor and contract research organization under the Alpha Research Institute name. It also plans to make and sell CBD edibles under the VitaCookies brand. It holds patent applications, trademarks and a portfolio of over 100 medical formulations.
This company has an open fundraising round.
Financials
FY2023–FY2025 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inDotted grey bars are our estimate for rounds that didn't state one: the round's share price × the shares outstanding in its filings. Same measure as blue, but rougher.
Cap table
Share counts as of Mar 27, 2026| Class | Outstanding | Votes / share | Share of total | Liquidation | Last price |
|---|---|---|---|---|---|
| Series B Preferredpreferred | 2,000 | — | 0% | paid 1st | — |
| Series A Preferredpreferred | 2,500,000 | — | 0.02% | — | — |
| Common Stock | 11,626,749,347 | — | 100.0% | — | $0.0004Apr 2026 |
| Total | 11,629,251,347 | 100% |
Shares outstanding over timein today's share terms
Changes in named holdersshares in today's terms · % of all shares at the time
- Rui Shen800K (6.92%) Sep 2009 → 5.7M (43.9%) Aug 2010 → 5.3M (40.2%) Sep 2011
- Whitebox Combined Partners751K (5.81%) Aug 2010 → 726K (5.51%) Sep 2011
Principal holders% as the filing states it, Mar 27, 2026
- Dante Picazo2,000,000 Series A Preferred80.0%of Series A Preferred
- John Jones1,000 Series B Preferred50.0%of Series B Preferred
- Dante Picazo1,000 Series B Preferred50.0%of Series B Preferred
- Dante Picazo4,002,611,700 Common Stock34.1%of
- John Jones2,123,888,888 Common Stock18.1%of
- Ibeth Coralles625,000,000 Common Stock5.3%of
- Jose Torres Torres165,000,000 Common Stock1.4%of
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
3 peopleNames and titles as disclosed on SEC Form 1-A. Bios and photos come from the platform campaign page and may be out of date.
SEC filings
View all 41 filings on EDGAR- Form 253G2Jul 1, 20260001683168-26-005213EDGAR
- Form 253G2May 21, 20260001683168-26-004216EDGAR
- Form 10-QApr 16, 20260001683168-26-003012EDGAR
- Form 253G2Apr 15, 20260001683168-26-002966EDGAR
- Form QUALIFApr 13, 20269999999994-26-000079EDGAR
- Form 1-AMar 27, 20260001683168-26-002344EDGAR
- Form 10-QFeb 19, 20260001683168-26-001190EDGAR
- Form 10-QOct 22, 20250001683168-25-007721EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.